WuXi Biologics (Shanghai) and WuXi Biologics Ireland have divulged antibody-drug conjugates (ADCs) comprising anti-TROP2 antibodies covalently linked to cytotoxic drugs via linker reported to be useful for the treatment of cancer.
RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer.
Vellore Institute of Technology University (VIT) and BG Negev Technologies and Applications have described new curcumin or piperine analogues acting as NF-kappaB (NFKB) activation inhibitors and/or quorum sensing signaling inhibitors reported to be useful for treatment of cancer, fungal and bacterial infections and inflammatory disorders.
GentiBio announced that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
Scientists at the Institute of Cancer Research (ICR) in London have discovered that melanoma cells spread by harnessing a gene normally involved in the development of the nervous system.
Tetra Bio-Pharma has announced new promising preclinical results with ARDS-003 (onternabez) from live SARS-CoV-2 virus infection studies, as well as a septic lung model, carried out by independent researchers.
Shionogi has reported that S-217622 (ensitrelvir fumaric acid), the company's orally administered antiviral drug for COVID-19, shows high in vitro antiviral activity against the SARS-CoV-2 Omicron subvariant BA.2.75.
Mount Sinai is leading a team of researchers that has been awarded a 3-year, USD 500,000 grant from Stand Up To Cancer (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene.
SELLAS Life Sciences has announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH-009, in solid cancer and acute myeloid leukemia (AML) cell lines.
RSS